Otlertuzumab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Otlertuzumab
- DrugBank Accession Number
- DB16275
- Background
Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Immunoglobulin, anti-(human cd antigen cd37) (synthetic human-mus musculus fragment tru-016), dimer
- Otlertuzumab
- External IDs
- TRU-016
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ULeukocyte antigen CD37 antibodyregulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2MZ3L2664T
- CAS number
- 1372645-37-8
References
- General References
- Not Available
- External Links
- Wikipedia
- Otlertuzumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment B-cell Small Lymphocytic Lymphoma Recurrent 1 1 Completed Treatment Chronic Lymphocytic Leukemia / Non-Hodgkin's Lymphoma (NHL) 1 1 Terminated Treatment Chronic Lymphocytic Leukemia / Peripheral T-Cell Lymphoma (PTCL) 1 1, 2 Completed Treatment Chronic Lymphocytic Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsLeukocyte antigen CD37
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- AntibodyRegulator
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- CD37
- Uniprot ID
- P11049
- Uniprot Name
- Leukocyte antigen CD37
- Molecular Weight
- 31702.91 Da
References
- Schnaiter A, Stilgenbauer S: Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget. 2010 Nov;1(7):472-82. doi: 10.18632/oncotarget.101103. [Article]
Drug created at December 15, 2020 18:17 / Updated at May 03, 2022 16:06